Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 580,074 | 724,531 | 761,515 | 619,802 | 605,440 |
| Marketable Securities | 572,017 | 567,006 | 512,253 | 489,945 | 450,798 |
| Receivables | 597,913 | 461,316 | 419,622 | 466,507 | 430,147 |
| Inventories | 918,921 | 894,083 | 839,460 | 802,315 | 786,356 |
| Other current assets | 173,180 | 104,521 | 149,851 | 139,029 | 121,283 |
| TOTAL | $2,842,105 | $2,751,457 | $2,682,701 | $2,517,598 | $2,394,024 |
| Non-Current Assets | |||||
| PPE Net | 1,068,142 | 1,073,366 | 1,051,821 | 1,049,464 | 1,039,544 |
| Investments And Advances | 340,635 | 333,835 | 372,302 | 412,503 | 462,827 |
| Intangibles | 522,188 | 534,768 | 550,223 | 565,567 | 570,450 |
| Other Non-Current Assets | 1,660,625 | 1,681,648 | 1,606,993 | 1,600,709 | 1,595,862 |
| TOTAL | $3,591,590 | $3,623,617 | $3,581,339 | $3,628,243 | $3,668,683 |
| Total Assets | $6,433,695 | $6,375,074 | $6,264,040 | $6,145,841 | $6,062,707 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 598,231 | 588,884 | 521,020 | 464,727 | 490,418 |
| TOTAL | $598,231 | $588,884 | $521,020 | $464,727 | $490,418 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,176,421 | 1,183,034 | 1,174,506 | 1,176,307 | 1,180,974 |
| TOTAL | $1,176,421 | $1,183,034 | $1,174,506 | $1,176,307 | $1,180,974 |
| Total Liabilities | $1,774,652 | $1,771,918 | $1,695,526 | $1,641,034 | $1,671,392 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 187,701 | 186,529 | 185,849 | 185,474 | 184,995 |
| Common Shares | 188 | 186 | 186 | 186 | 185 |
| Retained earnings | -738,347 | -789,199 | -788,949 | -777,227 | -804,891 |
| Other shareholders' equity | -20,671 | -12,726 | 21,424 | 9,182 | -10,266 |
| TOTAL | $4,659,043 | $4,603,156 | $4,568,514 | $4,504,807 | $4,391,315 |
| Total Liabilities And Equity | $6,433,695 | $6,375,074 | $6,264,040 | $6,145,841 | $6,062,707 |